Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Inhibition of SF3A2 acetylation at lysine 10 mediated by p300/SIRT7 promotes Fscn1 alternative splicing against myocardial ischemic/reperfusion injury

ABSTRACT: Inhibition of SF3A2 acetylation at lysine 10 mediated by p300/SIRT7 promotes Fscn1 alternative splicing against myocardial ischemic/reperfusion injury

PROVIDER: PRJNA991442 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25133731_1.fastq.gz	Fastqsanger.gz
	SRR25133732_1.fastq.gz	Fastqsanger.gz
	SRR25133733_1.fastq.gz	Fastqsanger.gz
	SRR25133734_1.fastq.gz	Fastqsanger.gz
	SRR25133735_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Inhibition of SF3A2 acetylation at lysine 10 mediated by p300/SIRT7 promotes Fscn1 alternative splicing against myocardial ischemic/reperfusion injury [RNA-Seq I]

Project description:The 4D-lable free proteomic and acetylomic study were employed to gain the targets of GS. The co-immunoprecipitation, co-localization, and specific acetylation site antibody were used to verify the acetylation. Based on the mass spectrometry analysis, the active monomers in GS were screened by phenotypes of acetylation and mitochondrial function. The mechanism was studied through RNA-seq, qPCR, cellular thermal shift assay, surface plasmon resonance, acetyltransferase activity combined with pharmacological inhibitor, RNA interference and site-specific mutation. These findings provide a novel mechanism underlying cardiomyocyte protection of ginsenoside Rb2 through p300/SIRT7-SF3A2-Fscn1 signaling and opens new opportunities for pharmacological prevention and treatment of ischemic and associated sequelae.

2024-12-13 | GSE236471 | GEO

Inhibition of SF3A2 acetylation at lysine 10 mediated by p300/SIRT7 promotes Fscn1 alternative splicing against myocardial ischemic/reperfusion injury [RNA-Seq I]

Project description:Inhibition of SF3A2 acetylation at lysine 10 mediated by p300/SIRT7 promotes Fscn1 alternative splicing against myocardial ischemic/reperfusion injury [RNA-Seq I]

| PRJNA991446 | ENA

Inhibition of SF3A2 acetylation at lysine 10 mediated by p300/SIRT7 promotes Fscn1 alternative splicing against myocardial ischemic/reperfusion injury

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-12-13 | GSE236473 | GEO

SIRT7 is a histone H3 lysine 18 deacetylase that regulates oncogenic transformation

Project description:Sirtuin proteins regulate diverse cellular pathways that influence genomic stability, metabolism, and ageing. SIRT7 is a mammalian sirtuin whose biochemical activity, molecular targets, and physiologic functions have been unclear. Here we show that SIRT7 is an NAD+-dependent, histone H3 acetyl-lysine 18 (H3K18Ac) deacetylase that stabilizes the transformed state of cancer cells. Genome-wide binding studies reveal that SIRT7 binds to promoters of a specific set of gene targets, where it deacetylates H3K18Ac and promotes transcriptional repression. The spectrum of SIRT7 target genes is defined in part by interaction of SIRT7 with the cancer-related ETS transcription factor ELK4, and comprises numerous genes with links to tumour suppression. Notably, selective hypoacetylation of H3K18Ac has recently been linked to oncogenic transformation, and in patients, is associated with aggressive tumour phenotypes and poor prognosis. We find that deacetylation of H3K18Ac by SIRT7 is necessary for maintaining essential features of human cancer cells including anchorage independent growth and escape from contact inhibition. Moreover, SIRT7 is necessary for a global hypoacetylation of H3K18Ac associated with cellular transformation by viral oncoproteins. Finally, SIRT7 depletion markedly reduces the tumourigenicity of human cancer cell xenografts in mice. Together, our work establishes SIRT7 as the first known site-specific H3K18Ac deacetylase and demonstrates a pivotal role for SIRT7 in chromatin regulation, cellular transformation programs, and tumour formation in vivo. SIRT7 ChIP-seq was performed in K562 cell lines under normal conditions. Two replicates were performed for both the SIRT7 ChIP as well as input control.

2012-05-06 | E-GEOD-28149 | biostudies-arrayexpress

SIRT7 is an RNA-activated protein lysine deacylase [RIP ribosomal RNA]

Project description:We report that RNA can increase the catalytic efficiency of SIRT7 and that SIRT7 can remove long chain fatty acyl groups more efficiently than removing acetyl groups. Truncation and mutagenesis studies revealed residues at both the amino and carboxyl termini of SIRT7 that are involved in RNA-binding and important for activity. RNA immunoprecipitation-sequencing (RIP-seq) identified ribosomal RNA (rRNA) as the predominant RNA binding partners of SIRT7. The associated RNA was able to effectively activate the deacetylase and defatty-acylase activities of SIRT7. These findings provide important insights into the biological functions of SIRT7, as well as an improved platform to develop SIRT7 modulators.

2017-02-17 | GSE81839 | GEO

SIRT7 is an RNA-activated protein lysine deacylase [RIP-seq ribo-zero]

2017-02-17 | GSE81840 | GEO

SIRT7 is a histone H3 lysine 18 deacetylase that regulates oncogenic transformation

2012-05-07 | GSE28149 | GEO

SIRT7 suppresses tumorigenesis by attenuating MYC activity

Project description:SIRT7 is a member of the mammalian sirtuin family of NAD+ dependent deacylases, and interacts with RNA polymerase I and UBF to regulate rDNA transcription. Various studies in mammalian cells and human clinical data have linked SIRT7 to cancer. However studies differ as to whether SIRT7 is oncogenic or tumor suppressive. Here we analyzed SIRT7 knockout mice and found SIRT7 deficiency caused sub-Mendelian birth numbers and a reduction in body size. Moreover, at 18 month of age, roughly 60 % of the SIRT7 knockout mice develop hepatocellular carcinoma (HCC), in many cases leading to suspected metastasis. Several HCC associated genes were up-regulated in livers of mice as young as 6 months of age, particularly targets of the proto-oncogene, c- MYC. Indeed SIRT7 interacts with MYC at endogenous protein levels and also represses MYC activity. Our findings thus show that SIRT7 acts as a tumor suppressor in vivo, and may suggest novel strategies to treat liver cancer. The mRNAs from 3 replicates of mouse Wildtype liver compared to 3 replicates of mouse liver lacking SIRT7

2014-08-20 | E-GEOD-50076 | biostudies-arrayexpress

SIRT7 liver

Project description:SIRT7 liver

| PRJNA896547 | ENA

the RNA binding property of FSCN1

Project description:To investigate the RNA binding property of FSCN1 in ESCC, RNA immunoprecipitation (RIP) was performed using an FSCN1 monoclonal antibody in ECA-109 cell lysate

2022-03-05 | GSE197621 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data